These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 2248079)

  • 41. Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide.
    Dingemanse J; Hussain Y; Korn A
    Int J Clin Pharmacol Ther; 1996 Apr; 34(4):172-7. PubMed ID: 8861736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RIMA: a safe concept in the treatment of depression with moclobemide.
    Amrein R; Hetzel W; Stabl M; Schmid-Burgk W
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():7-11. PubMed ID: 1394030
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A.
    Finberg JP
    Acta Psychiatr Scand Suppl; 1995; 386():8-13. PubMed ID: 7717096
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tyramine pressor response with moclobemide--a reversible monoamine oxidase inhibitor.
    Tiller JW; Maguire KP; Davies BM
    Psychiatry Res; 1987 Nov; 22(3):213-20. PubMed ID: 3432450
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
    Caille D; Bergis OE; Fankhauser C; Gardes A; Adam R; Charieras T; Grosset A; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):265-77. PubMed ID: 8613929
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of benzamide derivatives on rat brain monoamine oxidase activity in vitro].
    Gol'dina OA; Zagorevskiĭ VA; Lopatina KI; Sokolova TV; Gankina EM
    Biull Eksp Biol Med; 1986 Aug; 102(8):170-2. PubMed ID: 3742029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
    Kan JP; Steinberg R; Mouget-Goniot C; Worms P; Bizière K
    J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine.
    Waldmeier PC
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Mar; 17(2):183-98. PubMed ID: 8430214
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor.
    Korn A; Da Prada M; Raffesberg W; Allen S; Gasic S
    J Neural Transm Suppl; 1988; 26():57-71. PubMed ID: 3162952
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine.
    Korn A; Da Prada M; Raffesberg W; Gasic S; Eichler HG
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):17-23. PubMed ID: 2450251
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression.
    Lotufo-Neto F; Trivedi M; Thase ME
    Neuropsychopharmacology; 1999 Mar; 20(3):226-47. PubMed ID: 10063483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline.
    Dingemanse J; Kneer J; Wallnöfer A; Kettler R; Zürcher G; Koulu M; Korn A
    Clin Neuropharmacol; 1996 Oct; 19(5):399-414. PubMed ID: 8889283
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?
    Baker GB; Sowa B; Todd KG
    J Psychiatry Neurosci; 2007 Sep; 32(5):313-5. PubMed ID: 17823646
    [No Abstract]   [Full Text] [Related]  

  • 55. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interaction between orally administered tyramine and moclobemide.
    Zimmer R; Puech AJ; Philipp F; Korn A
    Acta Psychiatr Scand Suppl; 1990; 360():78-80. PubMed ID: 2248083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The current status of monoamine oxidase and its inhibitors.
    Jarrott B; Vajda FJ
    Med J Aust; 1987 Jun; 146(12):634-8. PubMed ID: 3114597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis, conformational analysis and antidepressant activity of moclobemide new analogues.
    Ghanbarpour A; Hadizadeh F; Piri F; Rashidi-Ranjbar P
    Pharm Acta Helv; 1997 Apr; 72(2):119-22. PubMed ID: 9112832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.
    Kumagae Y; Matsui Y; Iwata N
    Jpn J Pharmacol; 1991 Jan; 55(1):121-8. PubMed ID: 1904113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vivo characterization of T-794, a novel reversible inhibitor of monoamine oxidase-A, as an antidepressant with a wide safety margin.
    Kato M; Katayama T; Iwata H; Yamamura M; Matsuoka Y; Narita H
    J Pharmacol Exp Ther; 1998 Mar; 284(3):983-90. PubMed ID: 9495858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.